Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Neuroendocrine Tumors peptide trials
8 selected ClinicalTrials.gov records carrying the official condition label Neuroendocrine Tumors. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
8 selected records.
4 profiles.
2018–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 110 selected PubMed records and 32 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Neuroendocrine Tumors unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT03206060
PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- October 26, 2026
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT03590119
PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- November 8, 2022
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT04954820
PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- June 4, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Lutetium Lu 177 dotatate · 2026-11-12
ClinicalTrials.gov record NCT05178693
Recruiting at the retained observation.
Open attributed record →Gallium Ga 68 dotatate · 2026-10-26
ClinicalTrials.gov record NCT03206060
Recruiting at the retained observation.
Open attributed record →Lutetium Lu 177 dotatate · 2026-06-04
ClinicalTrials.gov record NCT04954820
Recruiting at the retained observation.
Open attributed record →Lutetium Lu 177 dotatate · 2025-07-22
ClinicalTrials.gov record NCT06395402
Recruiting at the retained observation.
Open attributed record →Octreotide · 2025-05-09
ClinicalTrials.gov record NCT03289741
Completed at the retained observation.
Open attributed record →Pasireotide · 2024-10-01
ClinicalTrials.gov record NCT01794793
Completed at the retained observation.
Open attributed record →Lutetium Lu 177 dotatate · 2022-11-08
ClinicalTrials.gov record NCT03590119
Completed at the retained observation.
Open attributed record →Pasireotide · 2018-10-18
ClinicalTrials.gov record NCT01469572
Completed at the retained observation.
Open attributed record →